Peter Adamson, MD, a pediatric oncologist at The Children's Hospital of Philadelphia and chair of the Children's Oncology Group (COG), has joined a key group of scientific experts, cancer leaders, and patient advocates in advising the scientific direction and goals of Vice President Joe Biden's National Cancer Moonshot Initiative.
On April 4, the National Cancer Institute (NCI), part of the National Institutes of Health, announced Dr. Adamson among the membership of this new Blue Ribbon Panel. The panel will serve as a working group of the presidentially appointed National Cancer Advisory Board (NCAB). Dr. Adamson, one of the nation's leading pediatric oncologists, was previously named to the NCAB in June 2015 by President Obama.
“Thanks to advances in science, we are now in a historically unique position to make profound improvements in the way we treat, detect, and prevent cancer,” said NIH Director Francis S. Collins, MD, PhD in the NIH announcement of the Blue Ribbon panel.
The panel will consider how to advance themes and approaches in cancer research that have been proposed to date, including cancer vaccines, highly sensitive approaches to early detection, immunotherapy and combination therapies, single-cell genomic profiling of cancer cells and cells in the tumor microenvironment, enhanced data sharing, and new approaches to the treatment of pediatric cancers. The panel will make recommendations to the NCAB, which will in turn make recommendations to the NCI.
“I am very pleased that there will be pediatric oncology representation on this important panel, and am honored to join colleagues in helping to support this effort,” said Dr. Adamson, who is also a professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Adamson has chaired the COG, the world's largest organization devoted exclusively to childhood and adolescent cancer research, since 2010. At CHOP, he served as chief of the Division of Clinical Pharmacology and Therapeutics, and director of the Office of Clinical and Translational Research. Prior to joining CHOP in 1999, he was a member of the Pediatric Oncology Branch of the NCI.
“We are deeply honored that Dr. Adamson has received this national acknowledgment of his profound expertise as a clinician and researcher in children's cancer, and we applaud his continued commitment to advancing treatment for children,” said Madeline Bell, president and CEO of CHOP.